High density lipoprotein: It's not just about lipid transport anymore

Trends in Endocrinology and Metabolism

Volumn 22, Issue 1, 2011, Pages 9-15

  Gordon, Scott M ^a   Hofmann, Susanna ^b   Askew, David S ^b   Davidson, W Sean ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER G1; APOLIPOPROTEIN A1; BACTERIUM LIPOPOLYSACCHARIDE; CD31 ANTIGEN; CELL ADHESION MOLECULE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIPOTEICHOIC ACID; MONOCYTE CHEMOTACTIC PROTEIN; NITRIC OXIDE; OXYSTEROL; SCAVENGER RECEPTOR B;

ANTIGEN EXPRESSION; ANTIMICROBIAL ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; BACTERIAL INFECTION; BLOOD VESSEL TONE; BONE MARROW CELL; CARDIOVASCULAR RISK; CELL MATURATION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; DIABETES MELLITUS; DNA VIRUS; EMBRYO DEVELOPMENT; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; IMMUNOMODULATION; INFLAMMATION; INFLAMMATORY CELL; INNATE IMMUNITY; INSULIN RESISTANCE; LEUKOCYTE; LIPID TRANSPORT; MACROPHAGE; METABOLIC REGULATION; MONOCYTE; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PARASITOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RNA VIRUS; STEM CELL; THROMBOCYTE FUNCTION; TISSUE REPAIR; VASCULAR ENDOTHELIUM; VIRUS ENTRY; VIRUS INFECTION;

ANIMALS; BIOLOGICAL TRANSPORT; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; EMBRYONIC DEVELOPMENT; HUMANS; IMMUNITY, INNATE; MODELS, BIOLOGICAL;

EID: 78650519284     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2010.10.001     Document Type: Review

References (73)

1. Lund-Katz S., Phillips M.C. High density lipoprotein structure-function and role in reverse cholesterol transport. Subcell. Biochem. 2010, 51:183-227.
2. Zhang Y., et al. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation 2003, 108:661-663.
3. Cockerill G.W., et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 1995, 15:1987-1994.
4. Patel S., et al. Anti-inflammatory effects of apolipoprotein A-I in the rabbit. Atherosclerosis 2010, 2:392-397.
5. Nobecourt E., et al. Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. Arterioscler. Thromb. Vasc. Biol. 2010, 30:766-772.
6. Tolle M., et al. HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1542-1548.
7. Mineo C., et al. Endothelial and antithrombotic actions of HDL. Circ. Res. 2006, 98:1352-1364.
8. Drew B.G., et al. High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:6999-7004.
9. Mineo C., et al. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J. Biol. Chem. 2003, 278:9142-9149.
10. Norata G.D., et al. High-density lipoproteins induce transforming growth factor-beta2 expression in endothelial cells. Circulation 2005, 111:2805-2811.
11. Yuhanna I.S., et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat. Med. 2001, 7:853-857.
12. Tarr P.T., et al. Emerging new paradigms for ABCG transporters. Biochim. Biophys. Acta 2009, 1791:584-593.
13. Terasaka N., et al. ATP-Binding Cassette Transporter G1 and High-Density Lipoprotein Promote Endothelial NO Synthesis Through a Decrease in the Interaction of Caveolin-1 and Endothelial NO Synthase. Arterioscler. Thromb. Vasc. Biol. 2010, 11:2219-2225.
14. Whetzel A.M., et al. ABCG1 deficiency in mice promotes endothelial activation and monocyte-endothelial interactions. Arterioscler. Thromb. Vasc. Biol. 2010, 30:809-817.
15. Murphy A.J., et al. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler. Thromb. Vasc. Biol. 2008, 28:2071-2077.
16. Okura H., et al. HDL/apolipoprotein A-I binds to macrophage-derived progranulin and suppresses its conversion into proinflammatory granulins. J. Atheroscler. Thromb. 2010, 17:568-577.
17. Murch O., et al. Lipoproteins in inflammation and sepsis. I. Basic science. Intensive Care Med. 2007, 33:13-24.
18. Jahangiri A. High-density lipoprotein and the acute phase response. Curr. Opin. Endocrinol. Diabetes Obes. 2010, 17:156-160.
19. Villarroel F., et al. Apolipoprotein A-I, an antimicrobial protein in Oncorhynchus mykiss: evaluation of its expression in primary defence barriers and plasma levels in sick and healthy fish. Fish. Shellfish. Immunol. 2007, 23:197-209.
20. Caipang C.M., et al. Intraperitoneal vaccination of Atlantic cod, Gadus morhua with heat-killed Listonella anguillarum enhances serum antibacterial activity and expression of immune response genes. Fish. Shellfish. Immunol. 2008, 24:314-322.
21. Johnston L.D., et al. Apolipoprotein A-I from striped bass (Morone saxatilis) demonstrates antibacterial activity in vitro. Comp Biochem. Physiol B Biochem. Mol. Biol. 2008, 151:167-175.
22. Figueiredo P.M., et al. Serum high-density lipoprotein (HDL) inhibits in vitro enterohemolysin (EHly) activity produced by enteropathogenic Escherichia coli. FEMS Immunol. Med. Microbiol. 2003, 38:53-57.
23. Grunfeld C., et al. Lipoproteins inhibit macrophage activation by lipoteichoic acid. J. Lipid Res. 1999, 40:245-252.
24. Ma J., et al. Role of apolipoprotein A-I in protecting against endotoxin toxicity. Acta Biochim. Biophys. Sin. (Shanghai) 2004, 36:419-424.
25. Parker T.S., et al. Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole blood. Infect. Immun. 1995, 63:253-258.
26. Jiao Y.L., Wu M.P. Apolipoprotein A-I diminishes acute lung injury and sepsis in mice induced by lipoteichoic acid. Cytokine 2008, 43:83-87.
27. Li Y., et al. Human ApoA-I overexpression diminishes LPS-induced systemic inflammation and multiple organ damage in mice. Eur. J. Pharmacol. 2008, 590:417-422.
28. Singh I.P., et al. Lipoproteins account for part of the broad non-specific antiviral activity of human serum. Antiviral Res. 1999, 42:211-218.
29. Srinivas R.V., et al. Inhibition of virus-induced cell fusion by apolipoprotein A-I and its amphipathic peptide analogs. J. Cell Biochem. 1991, 45:224-237.
30. Wheeler R.J. The trypanolytic factor-mechanism, impacts and applications. Trends Parasitol 2010, 9:457-464.
31. Hajduk S.L., et al. Lysis of Trypanosoma brucei by a toxic subspecies of human high density lipoprotein. J. Biol. Chem. 1989, 264:5210-5217.
32. Vanhollebeke B., Pays E. The trypanolytic factor of human serum: many ways to enter the parasite, a single way to kill. Mol. Microbiol. 2010, 76:806-814.
33. Vanhamme L., et al. Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature 2003, 422:83-87.
34. Raper J., et al. Characterization of a novel trypanosome lytic factor from human serum. Infect. Immun. 1999, 67:1910-1916.
35. Tomlinson S., et al. High-density-lipoprotein-independent killing of Trypanosoma brucei by human serum. Mol. Biochem. Parasitol. 1995, 70:131-138.
36. Vanhollebeke B., et al. A haptoglobin-hemoglobin receptor conveys innate immunity to Trypanosoma brucei in humans. Science 2008, 320:677-681.
37. Samanovic M., et al. Trypanosome lytic factor, an antimicrobial high-density lipoprotein, ameliorates Leishmania infection. PLoS Pathog. 2009, 5:e1000276.
38. Van L.S., et al. High-density lipoprotein at the interface of type 2 diabetes mellitus and cardiovascular disorders. Curr. Pharm. Des. 2010, 16:1504-1516.
39. Mooradian A.D., et al. Transcriptional control of apolipoprotein A-I gene expression in diabetes. Diabetes 2004, 53:513-520.
40. Han R., et al. Apolipoprotein A-I stimulates AMP-activated protein kinase and improves glucose metabolism. Diabetologia 2007, 50:1960-1968.
41. Drew B.G., et al. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 2009, 119:2103-2111.
42. Fryirs M.A., et al. Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1642-1648.
43. Brunham L.R., et al. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat. Med. 2007, 13:340-347.
44. Peterson S.J., et al. L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice. J. Lipid Res. 2008, 49:1658-1669.
45. Peterson S.J., et al. The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice. J. Lipid Res. 2009, 50:1293-1304.
46. Ruan X., et al. Apolipoprotein A-I possesses an anti-obesity effect associated with increase of energy expenditure and upregulation of UCP1 in brown fat. J. Cell Mol. Med. 2010.
47. de Souza J.A., et al. Small, dense HDL 3 particles attenuate apoptosis in endothelial cells: pivotal role of apolipoprotein A-I. J. Cell Mol. Med. 2010, 14:608-620.
48. Fuhrman B., et al. Paraoxonase 1 (PON1) deficiency in mice is associated with reduced expression of macrophage SR-BI and consequently the loss of HDL cytoprotection against apoptosis. Atherosclerosis 2010, 211:61-68.
49. Ortiz-Munoz G., et al. HDL antielastase activity prevents smooth muscle cell anoikis, a potential new antiatherogenic property. FASEB J. 2009, 23:3129-3139.
50. Frias M.A., et al. Native and reconstituted HDL protect cardiomyocytes from doxorubicin-induced apoptosis. Cardiovasc. Res. 2010, 85:118-126.
51. Theilmeier G., et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 2006, 114:1403-1409.
52. Kontush A., et al. Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler. Thromb. Vasc. Biol. 2007, 27:1843-1849.
53. Rutti S., et al. Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells. Endocrinology 2009, 150:4521-4530.
54. Terasaka N., et al. High-density lipoprotein protects macrophages from oxidized low-density lipoprotein-induced apoptosis by promoting efflux of 7-ketocholesterol via ABCG1. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:15093-15098.
55. Yvan-Charvet L., et al. ABCA1 and ABCG1 protect against oxidative stress-induced macrophage apoptosis during efferocytosis. Circ. Res. 2010, 106:1861-1869.
56. Radojkovic C., et al. Stimulation of cell surface F1-ATPase activity by apolipoprotein A-I inhibits endothelial cell apoptosis and promotes proliferation. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1125-1130.
57. Brodeur M.R., et al. HDL3 reduces the association and modulates the metabolism of oxidized LDL by osteoblastic cells: a protection against cell death. J. Cell Biochem. 2008, 105:1374-1385.
58. de Souza J.A., et al. Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity. Atherosclerosis 2008, 197:84-94.
59. Mythreye K., et al. ApoA-I induced CD31 in bone marrow-derived vascular progenitor cells increases adhesion: implications for vascular repair. Biochim. Biophys. Acta 2008, 1781:703-709.
60. Yvan-Charvet L., et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science 2010, 328:1689-1693.
61. Fujimoto V.Y., et al. High-density lipoprotein metabolism and the human embryo. Hum. Reprod. Update. 2010, 16:20-38.
62. Browne R.W., et al. Follicular fluid high density lipoprotein-associated micronutrient levels are associated with embryo fragmentation during IVF. J. Assist. Reprod. Genet. 2009, 26:557-560.
63. Yesilaltay A., et al. Effects of hepatic expression of the high-density lipoprotein receptor SR-BI on lipoprotein metabolism and female fertility. Endocrinology 2006, 147:1577-1588.
64. Nofer J.R., et al. High-density lipoproteins, platelets and the pathogenesis of atherosclerosis. Clin. Exp. Pharmacol. Physiol. 2010, 37:726-735.
65. Dole V.S., et al. Thrombocytopenia and platelet abnormalities in high-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1111-1116.
66. Calkin A.C., et al. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation 2009, 120:2095-2104.
67. Gordon S.M., et al. Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography. J. Proteome. Res. 2010, 9:5239-5249.
68. Gordon S., et al. High-density lipoprotein proteomics: Identifying new drug targets and biomarkers by understanding functionality. Curr. Cardio. Risk Rep. 2010, 4:1-8.
69. Heinecke J.W. The HDL proteome: a marker--and perhaps mediator--of coronary artery disease. J. Lipid Res. 2009, 50(Suppl.):S167-171.
70. Courtney H.S., et al. Serum opacity factor, a streptococcal virulence factor that binds to apolipoproteins A-I and A-II and disrupts high density lipoprotein structure. J. Biol. Chem. 2006, 281:5515-5521.
71. Genovese G., et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010, 329:841-845.
72. Tang C., et al. Janus kinase 2 modulates the apolipoprotein interactions with ABCA1 required for removing cellular cholesterol. J. Biol. Chem. 2004, 279:7622-7628.
73. Tang C., et al. The macrophage cholesterol exporter ABCA1 functions as an anti-inflammatory receptor. J. Biol. Chem. 2009, 284:32336-32343.